PCSK9 and Cognitive impairment: Cardiovascular disease (CVD) is still the leading cause of worldwide mortality, causing more than 18.6 million deaths each year and affecting the development of cognitive impairment in the elderly.[1,2] Although lifestyle changes can reduce CVD risk, lipid-lowering drugs such as statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, ezetimibe, and fibrates remain important tools for managing cardiovascular health in high-risk patients and have been widely used in clinical practice.